2023
EPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018
Neff C, Price M, Gerstl J, Kruchko C, Barnholtz-Sloan J, Bernstock J, Smith T, Claus E, Ostrom Q. EPID-28. YEARS OF LIFE LOST FOR BRAIN AND OTHER CENTRAL NERVOUS SYSTEM TUMORS IN THE UNITED STATES, 2018. Neuro-Oncology 2023, 25: v121-v121. PMCID: PMC10639734, DOI: 10.1093/neuonc/noad179.0460.Peer-Reviewed Original ResearchCentral nervous system tumorsNervous system tumorsTotal YLLYears of lifeSystem tumorsAtypical teratoid/rhabdoid tumorCancer-specific mortalityShorter survival timeNon-malignant tumorsCDC's National ProgramNational Vital Statistics SystemRace/ethnicityAge of deathNational burdenCancer morbidityVital Statistics SystemSpecific histopathologyRhabdoid tumorSurvival timeLife LostPremature deathTumorsYLLNational programMortality dataTranscriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours
Nabbi A, Beck P, Delaidelli A, Oldridge D, Sudhaman S, Zhu K, Yang S, Mulder D, Bruce J, Paulson J, Raman P, Zhu Y, Resnick A, Sorensen P, Sill M, Brabetz S, Lambo S, Malkin D, Johann P, Kool M, Jones D, Pfister S, Jäger N, Pugh T. Transcriptional immunogenomic analysis reveals distinct immunological clusters in paediatric nervous system tumours. Genome Medicine 2023, 15: 67. PMID: 37679810, PMCID: PMC10486055, DOI: 10.1186/s13073-023-01219-x.Peer-Reviewed Original ResearchConceptsChimeric antigen receptorNervous system tumorsImmune clustersImmunogenomic analysisSystem tumorsCancer typesImmune checkpoint inhibitorsT-cell therapyPaediatric solid tumoursTumor mutational burdenImmune cell frequenciesPotential immune biomarkersImmune infiltration levelsB cell repertoireDeterminants of immune responseVariable response ratesBackgroundCancer immunotherapyImmunogenomic profilingMyeloid predominanceCheckpoint inhibitorsImmunotherapeutic strategiesImmunotherapy approachesImmune compositionImmune neutralizationImmune desertPersonality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI)
Puthenpura V, Nadkarni S, DiLuna M, Hieftje K, Marks A. Personality Changes and Staring Spells in a 12-Year-Old Child: A Case Report Incorporating ChatGPT, a Natural Language Processing Tool Driven by Artificial Intelligence (AI). Cureus 2023, 15: e36408. PMID: 37090271, PMCID: PMC10115215, DOI: 10.7759/cureus.36408.Peer-Reviewed Original ResearchLow-grade gliomasIntracranial tumorsPersonality changesTreatment of LGGCentral nervous system tumorsMain presenting featuresBroad differential diagnosisNervous system tumorsPresenting featuresPediatric patientsCase reportSystem tumorsFavorable outcomeEndocrine conditionsMain symptomsDifferential diagnosisIntracranial neoplasmsBrain tumorsGrade gliomasEarly identificationSymptomsTumorsOlder childrenCommon typeNatural language processing toolsRisk of early death in adolescents and young adults with cancer: a population-based study
Berkman A, Andersen C, Hildebrandt M, Livingston J, Green A, Puthenpura V, Peterson S, Milam J, Miller K, Freyer D, Roth M. Risk of early death in adolescents and young adults with cancer: a population-based study. Journal Of The National Cancer Institute 2023, 115: 447-455. PMID: 36682385, PMCID: PMC10086632, DOI: 10.1093/jnci/djac206.Peer-Reviewed Original ResearchConceptsCentral nervous system tumorsNervous system tumorsEarly deathHematologic malignanciesSolid tumorsCancer typesInsurance statusSystem tumorsYoung adultsEnd Results registrySocioeconomic statusPopulation-based studyLow socioeconomic statusSupportive careHigh riskSociodemographic factorsAYAsTumorsHealth systemMalignancyCancerDeathRiskDeath percentageDiagnosisClinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing
Galbraith K, Vasudevaraja V, Serrano J, Shen G, Tran I, Abdallat N, Wen M, Patel S, Movahed-Ezazi M, Faustin A, Spino-Keeton M, Roberts L, Maloku E, Drexler S, Liechty B, Pisapia D, Krasnozhen-Ratush O, Rosenblum M, Shroff S, Boué D, Davidson C, Mao Q, Suchi M, North P, Hopp A, Segura A, Jarzembowski J, Parsons L, Johnson M, Mobley B, Samore W, McGuone D, Gopal P, Canoll P, Horbinski C, Fullmer J, Farooqi M, Gokden M, Wadhwani N, Richardson T, Umphlett M, Tsankova N, DeWitt J, Sen C, Placantonakis D, Pacione D, Wisoff J, Hidalgo E, Harter D, William C, Cordova C, Kurz S, Barbaro M, Orringer D, Karajannis M, Sulman E, Gardner S, Zagzag D, Tsirigos A, Allen J, Golfinos J, Snuderl M. Clinical utility of whole-genome DNA methylation profiling as a primary molecular diagnostic assay for central nervous system tumors—A prospective study and guidelines for clinical testing. Neuro-Oncology Advances 2023, 5: vdad076. PMID: 37476329, PMCID: PMC10355794, DOI: 10.1093/noajnl/vdad076.Peer-Reviewed Original ResearchCNS tumorsProspective studyHistologic diagnosisCentral nervous system tumorsDiagnostic accuracyCentral nervous system cancerPrimary CNS tumorsNervous system tumorsNervous system cancersCancer-associated deathsClinical trial designDiagnostic errorsPrimary diagnostic methodDNA methylation profilingMolecular diagnostic testsPrognostic subclassificationPediatric patientsHistologic subtypeWhole genome DNA methylation profilingDefinitive diagnosisPrognostic informationSystem tumorsSystem cancersPatient managementClinical utility
2022
The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors
Gueble SE, Vasquez JC, Bindra RS. The Role of PARP Inhibitors in Patients with Primary Malignant Central Nervous System Tumors. Current Treatment Options In Oncology 2022, 23: 1566-1589. PMID: 36242713, PMCID: PMC12184665, DOI: 10.1007/s11864-022-01024-5.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsHomologous recombination deficiencyPrimary CNS tumorsCNS tumorsClinical trialsPARP inhibitorsPreclinical evidencePrimary malignant central nervous system tumorMalignant central nervous system tumorsCentral nervous system tumorsImmune checkpoint inhibitorsStandard treatment modalityInitial clinical trialsEarly phase trialsNervous system tumorsCentral nervous tumorsExtracranial cancerCheckpoint inhibitorsDevastating malignancyStandard therapyOngoing trialsCombination therapyTreatment optionsTreatment modalitiesSystem tumorsPhase trialsCell death in development, maintenance, and diseases of the nervous system
Mercau ME, Patwa S, Bhat KPL, Ghosh S, Rothlin CV. Cell death in development, maintenance, and diseases of the nervous system. Seminars In Immunopathology 2022, 44: 725-738. PMID: 35508671, DOI: 10.1007/s00281-022-00938-4.Peer-Reviewed Reviews, Practice Guidelines, Standards, and Consensus StatementsConceptsCell deathTissue-level responsesNervous system homeostasisNervous systemCentral nervous system tumorsMolecular modalitiesAcute brain injuryNervous system tumorsChronic neurodegenerative diseasesSystem homeostasisDead cellsNew therapeutic strategiesNeurodegenerative diseasesMechanisms of disposalGlial cellsNovel understandingAdult neurogenesisSystem tumorsBrain injuryPathological responseDisease statesTherapeutic strategiesCellsRecent studiesDeathPatient-Derived Xenotransplant of CNS Neoplasms in Zebrafish: A Systematic Review
Sarmiento B, Callegari S, Ghotme K, Akle V. Patient-Derived Xenotransplant of CNS Neoplasms in Zebrafish: A Systematic Review. Cells 2022, 11: 1204. PMID: 35406768, PMCID: PMC8998145, DOI: 10.3390/cells11071204.Peer-Reviewed Original ResearchConceptsAssociated with poor survivalCentral nervous system tumorsNervous system tumorsCentral nervous system malignant tumorNeuro-oncology fieldPrimary cell culturesSystem malignant tumorResults of xenotransplantationCNS tumorsTumor microenvironmentSystem tumorsCNS neoplasmsMalignant tumorsTumor progressionPediatric populationPoor survivalTumorImprove outcomesCarcinogenic processMolecular genotypingSystematic reviewNeuroblastomaEffects of different treatmentsGlioblastomaZebrafish modelInternational patterns and trends of childhood and adolescent cancer, 1978-2012
Zhao Y, Sun P, Xiao J, Jin L, Ma N, Li Z, Feng G, Huang H, Deziel N, Ma X, Ni X, Zhang Y. International patterns and trends of childhood and adolescent cancer, 1978-2012. Journal Of The National Cancer Center 2022, 2: 78-89. PMID: 39034956, PMCID: PMC11256536, DOI: 10.1016/j.jncc.2022.02.001.Peer-Reviewed Original ResearchCancer incidence ratesIncidence rateCancer incidenceMalignant central nervous system tumorsCentral nervous system tumorsOverall childhood cancerIncidence of lymphomaNervous system tumorsLeukemia incidence ratesSystem tumorsTesticular cancerChildhood cancerThyroid cancerAdolescent cancerKidney cancerJoinpoint regressionCancer incidentsAge groupsCancerCancer typesIncidenceTemporal trendsMethods DataAdolescentsChildren
2021
Hemorrhage Into a Subependymal Giant Cell Astrocytoma in an Adult With Tuberous Sclerosis
Barbiero FJ, Huttner AJ, Fulbright RK, Baehring JM. Hemorrhage Into a Subependymal Giant Cell Astrocytoma in an Adult With Tuberous Sclerosis. The Neurologist 2021, 26: 122-124. PMID: 34190204, DOI: 10.1097/nrl.0000000000000338.Peer-Reviewed Original ResearchConceptsIntracranial hemorrhageMagnetic resonance imaging (MRI) brainSubependymal giant cell astrocytomaCentral nervous system tumorsYoung adultsLife-threatening complicationsGiant cell astrocytomaNervous system tumorsTuberous sclerosis complexForamen of MonroRare genetic disorderGerm-line mutationsUncommon causeHematoma evacuationDiagnostic delaySpontaneous hemorrhageUnusual causeSubependymal nodulesSurveillance imagingSkin changesTumor resectionSystem tumorsAdenoma sebaceumTuberous sclerosisSkin lesionsLongitudinal Evaluation of Neuromuscular Dysfunction in Long-term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study
Rodwin RL, Chen Y, Yasui Y, Leisenring WM, Gibson TM, Nathan PC, Howell RM, Krull KR, Mohrmann C, Hayashi RJ, Chow EJ, Oeffinger KC, Armstrong GT, Ness KK, Kadan-Lottick NS. Longitudinal Evaluation of Neuromuscular Dysfunction in Long-term Survivors of Childhood Cancer: A Report from the Childhood Cancer Survivor Study. Cancer Epidemiology Biomarkers & Prevention 2021, 30: 1536-1545. PMID: 34099519, PMCID: PMC8523186, DOI: 10.1158/1055-9965.epi-21-0154.Peer-Reviewed Original ResearchConceptsChildhood Cancer Survivor StudyChildhood cancer survivorsCancer Survivor StudyNeuromuscular dysfunctionCumulative incidenceSpinal radiotherapyYears postdiagnosisCancer survivorsPrevalence ratiosSurvivor StudyCentral nervous system tumorsLong-term survivorsNervous system tumorsLater obesityRadiotherapy doseCNS tumorsSystem tumorsChildhood cancerMultivariable modelPlatinum exposureDysfunctionLongitudinal evaluationSurvivorsPrevalenceRadiation exposureRacial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors
Puthenpura V, Canavan ME, Poynter JN, Roth M, Pashankar FD, Jones BA, Marks AM. Racial/ethnic, socioeconomic, and geographic survival disparities in adolescents and young adults with primary central nervous system tumors. Pediatric Blood & Cancer 2021, 68: e28970. PMID: 33704901, PMCID: PMC8221084, DOI: 10.1002/pbc.28970.Peer-Reviewed Original ResearchConceptsHazard of deathCentral nervous system tumorsNervous system tumorsRace/ethnicitySocioeconomic statusSystem tumorsMultivariate Cox proportional hazards modelNon-Hispanic black patientsNon-Hispanic white patientsPrimary central nervous system tumorsCox proportional hazards modelEnd Results (SEER) databaseRetrospective cohort studyPrimary CNS tumorsYoung adult patientsNeuro-oncology patientsProportional hazards modelLowest SES tertileLow socioeconomic statusNHB patientsAYA patientsHazard ratioNHW patientsAdult patientsCohort study
2020
Diagnosis of digestive system tumours
Washington M, Goldberg R, Chang G, Limburg P, Lam A, Salto‐Tellez M, Arends M, Nagtegaal I, Klimstra D, Rugge M, Schirmacher P, Lazar A, Odze R, Carneiro F, Fukayama M, Cree I, Board W. Diagnosis of digestive system tumours. International Journal Of Cancer 2020, 148: 1040-1050. PMID: 32674220, DOI: 10.1002/ijc.33210.Peer-Reviewed Original ResearchConceptsDiagnosis of tumorsNeuroendocrine tumorsClassification of neuroendocrine tumorsWHO classification of tumorsLiquid biopsy resultsDysplasia to carcinomaWHO blue bookClassification of tumorsDigestive system tumorsBiopsy resultsWHO classificationGenetic abnormalitiesPrecancerous lesionsSystem tumorsBiliary tractMalignant processDiagnostic InnovationsCare of patientsTumorTreatment selectionClinical practiceOutcome predictionCarcinomaPatientsDiagnosisSocioeconomic status and childhood central nervous system tumors in California
Francis SS, Wang R, Enders C, Prado I, Wiemels JL, Ma X, Metayer C. Socioeconomic status and childhood central nervous system tumors in California. Cancer Causes & Control 2020, 32: 27-39. PMID: 33113073, DOI: 10.1007/s10552-020-01348-3.Peer-Reviewed Original ResearchConceptsPrimary CNS tumorsCentral nervous system tumorsChildhood CNS tumorsCNS tumorsNervous system tumorsSocioeconomic statusSystem tumorsChildhood central nervous system tumorsCalifornia Cancer RegistryCalifornia birth recordsSubset of subjectsHigher socioeconomic statusCancer RegistryCancer mortalitySubgroup analysisRisk factorsChildhood cancerSubsequent riskEmbryonal tumorsParental socioeconomic statusInsurance utilizationBirth recordsTumorsMedian household incomeSpecific exposures
2017
Parental Age and Risk of Pediatric Cancer in the Offspring: A Population-Based Record-Linkage Study in California
Wang R, Metayer C, Morimoto L, Wiemels JL, Yang J, DeWan AT, Kang A, Ma X. Parental Age and Risk of Pediatric Cancer in the Offspring: A Population-Based Record-Linkage Study in California. American Journal Of Epidemiology 2017, 186: 843-856. PMID: 28535175, PMCID: PMC5860074, DOI: 10.1093/aje/kwx160.Peer-Reviewed Original ResearchConceptsRecord linkage studyMaternal ageOdds ratioPediatric cancerParental agePopulation-based record linkage studyCentral nervous system tumorsRisk of lymphomaPopulation-based studyCancer registry dataNervous system tumorsRisk of leukemiaAge group 0Ages 0Pediatric cancer riskOlder paternal ageOlder age groupsTypes of cancerSystem tumorsRegistry dataCancer riskHigh riskGroup 0Birth recordsAge groupsA Comparison between the Diagnostic Accuracy of Frozen Section and Permanent Section Analyses in Central Nervous System
Amraei R, Moradi A, Zham H, Ahadi M, Baikpour M, Rakhshan A. A Comparison between the Diagnostic Accuracy of Frozen Section and Permanent Section Analyses in Central Nervous System. Asian Pacific Journal Of Cancer Prevention 2017, 18: 659-666. PMID: 28440972, PMCID: PMC5464481, DOI: 10.22034/apjcp.2017.18.3.659.Peer-Reviewed Original ResearchCentral nervous system tumorsNervous system tumorsCentral nervous systemFrozen sectionsSystem tumorsNervous systemPermanent section analysisDescriptive retrospective studyIntra-operative diagnosisCNS surgeryCNS lesionsPathologic evaluationRadiologic findingsCNS tumorsRetrospective studyHistopathological evaluationClinical historyDefinite diagnosisMedical recordsPathology reportsDiagnostic acuityPosterior fossaTumor categoryMiddle fossaPatients
2015
Advances in Radiation Therapy in Pediatric Neuro-oncology
Bindra RS, Wolden SL. Advances in Radiation Therapy in Pediatric Neuro-oncology. Journal Of Child Neurology 2015, 31: 506-516. PMID: 26271789, DOI: 10.1177/0883073815597758.Peer-Reviewed Original ResearchConceptsPediatric central nervous system tumorsCentral nervous system tumorsNervous system tumorsSystem tumorsRadiation therapyPediatric neuro-oncologyLong-term survivalEffective therapyTreatment protocolNeuro-oncologyBrain tumorsTherapyPrecision treatmentTumorsMolecular classificationMore childrenHealthy tissueImage guidanceProton therapyLess exposureTreatmentDoses
2012
A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy
Marks AM, Packer RJ. A Review of Secondary Central Nervous System Tumors After Treatment of a Primary Pediatric Malignancy. Seminars In Pediatric Neurology 2012, 19: 43-48. PMID: 22641075, DOI: 10.1016/j.spen.2012.02.015.Peer-Reviewed Original ResearchConceptsCentral nervous system tumorsSecondary central nervous system tumorsNervous system tumorsPediatric malignanciesSystem tumorsPrimary brain tumorsRole of treatmentCancer predisposition syndromeTreatment of leukemiaSecondary malignanciesSecondary tumorsBrain tumorsPredisposition syndromeMalignancyTumorsTreatmentRemarkable stridesSyndromeEtiologyLeukemiaIncidenceDiagnosis
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply